TALS
Price:
$2.72
Market Cap:
$116.44M
Talaris Therapeutics, Inc. operates as a late-clinical stage cell therapy company in the United States. The company engages in developing a method of allogeneic hematopoietic stem cell transplantation to transform the standard of care in solid organ transplantation and severe autoimmune diseases, as well as severe non-malignant blood, immune, and metabolic disorders. Its lead product candidate is FCR001, a novel allogeneic cell therapy that is in Phase II trial for living donor kidney transplant patients. The company is also developing FCR002 in deceased donor kidney transplants; FCR001 in patients with a severe form of scleroderma; and FCR001 for one or more severe non-malignant blood, immu...[Read more]
Industry
Biotechnology
IPO Date
2021-05-07
Stock Exchange
NASDAQ
Ticker
TALS
According to Talaris Therapeutics, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -1.56. This represents a change of 672.07% compared to the average of -0.20 of the last 4 quarters.
The mean historical PE Ratio of Talaris Therapeutics, Inc. over the last ten years is -0.51. The current -1.56 PE Ratio has changed 30.52% with respect to the historical average. Over the past ten years (40 quarters), TALS's PE Ratio was at its highest in in the December 2022 quarter at -0.07. The PE Ratio was at its lowest in in the June 2020 quarter at -18.46.
Average
-0.51
Median
-0.53
Minimum
-0.92
Maximum
-0.06
Discovering the peaks and valleys of Talaris Therapeutics, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 93.49%
Maximum Annual PE Ratio = -0.06
Minimum Annual Increase = -93.38%
Minimum Annual PE Ratio = -0.92
Year | PE Ratio | Change |
---|---|---|
2022 | -0.06 | -93.38% |
2021 | -0.92 | 93.49% |
2020 | -0.48 | -17.38% |
The current PE Ratio of Talaris Therapeutics, Inc. (TALS) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
-0.49
5-year avg
-0.51
10-year avg
-0.51
Talaris Therapeutics, Inc.’s PE Ratio is greater than Edgewise Therapeutics, Inc. (-14.14), less than Adicet Bio, Inc. (-0.98), greater than Cullinan Oncology, Inc. (-6.96), less than Vor Biopharma Inc. (-0.53), less than CytomX Therapeutics, Inc. (9.19), less than Instil Bio, Inc. (-0.78), less than Neoleukin Therapeutics, Inc. (-0.98), less than Spero Therapeutics, Inc. (4.06), greater than Assembly Biosciences, Inc. (-2.10), less than Nuvation Bio Inc. (-1.34), less than Achilles Therapeutics plc (-0.45), less than NextCure, Inc. (-0.65), greater than Ovid Therapeutics Inc. (-2.43), greater than Connect Biopharma Holdings Limited (-3.00),
Company | PE Ratio | Market cap |
---|---|---|
-14.14 | $1.64B | |
-0.98 | $121.95M | |
-6.96 | $1.04B | |
-0.53 | $62.11M | |
9.19 | $93.74M | |
-0.78 | $92.68M | |
-0.98 | $8.20M | |
4.06 | $71.07M | |
-2.10 | $107.81M | |
-1.34 | $692.60M | |
-0.45 | $29.58M | |
-0.65 | $39.73M | |
-2.43 | $72.39M | |
-3.00 | $68.88M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Talaris Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Talaris Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Talaris Therapeutics, Inc.'s PE Ratio?
How is the PE Ratio calculated for Talaris Therapeutics, Inc. (TALS)?
What is the highest PE Ratio for Talaris Therapeutics, Inc. (TALS)?
What is the 3-year average PE Ratio for Talaris Therapeutics, Inc. (TALS)?
What is the 5-year average PE Ratio for Talaris Therapeutics, Inc. (TALS)?
How does the current PE Ratio for Talaris Therapeutics, Inc. (TALS) compare to its historical average?